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ABSTRACT
Objectives: Cost-effectiveness analyses are routinely based
on data from group averages, restricting its generalizibility to
those with below- or above-average risk. A pharmaco-
economic model that used individualized risks for fractures
was developed in order to take into account patient
heterogeneity.
Methods: Data were obtained from The Health Improve-
ment Network research database of general practitioners,
comprising a UK general population of women aged more
than 50 years (N = 330,000). Mortality and hip, vertebral,
and other osteoporotic fracture risks for each individual were
estimated by age, body mass index (BMI), smoking, and
other clinical risk factors. Estimates on costs, EuroQol (EQ-
5D) utilities, and treatment efﬁcacy were obtained from a UK
national report (the National Institute for Clinical Excel-
lence) and outcomes were simulated over a 10-year period.
Results: It was found that the cost per quality-adjusted life-
year (QALY) gained was lower in elderly women and in
women with fracture history. There was a large variability in
the cost-effectiveness with baseline fracture risk and with
clinical risk factors. Patients with low BMI (<20) had con-
siderable better cost-effectiveness than patients with high
BMI (26). Using a cost-acceptability ratio of £30k per
QALY gained, bisphosphonate treatment became cost-
effective for patients with a 5-year risk of 9.3% (95% con-
ﬁdence interval [CI] 8.0–10.5%) for osteoporotic fractures
and of 2.1% (95% CI 1.5–2.7%) for hip fractures. Including
bone mineral density in the risk assessment, the cost per
QALY gained was £35k in women at age 60 with a fracture
history and a T-score of -2.5 (at age 80, this was £3k).
Conclusion: A pharmacoeconomic model based on indi-
vidual long-term risks of fracture improves the selection of
postmenopausal women for cost-effective treatment with
bisphosphonates.
Keywords: cost-effectiveness, fracture, osteoporosis, post-
menopausal women, risedronate.
Introduction
Economic evaluations are increasingly used as a guide
to allocate resources in health care [1]. In the ﬁeld of
the osteoporosis, a large number of cost-effectiveness
analyses have now been conducted [2,3]. The typical
approach in cost-effectiveness analyses is that of eco-
nomic modeling, with simulation studies that vary the
probabilities of various health states. These probabili-
ties are typically derived from literature and based on
population averages. The use of population averages in
economic modeling can limit the generalizibility of
cost-effectiveness results to patients with below- or
above-average risk. For example, a low body mass
index (BMI) is associated with a higher mortality than
individuals with an average BMI. Thus, individuals
with low BMI have a different cost-effectiveness com-
pared with individuals with average BMI.
It has been suggested that intervention thresholds
should be based on long-term fracture probability
rather than on age and speciﬁc levels of bone mineral
density (BMD) [4]. The reason for this view is that
BMD is only one component of the risk of fracture and
there are several clinical risk factors that contribute to
fracture risk independent of BMD. To date, there have
been no cost-effectiveness analyses that took into
account the heterogeneity in clinical risk factors in the
population. The objective of this study was to estimate
the intervention threshold for cost-effectiveness of bis-
phosphonate therapy, using individual estimates for
the risks of fracture.
Methods
Study Population
The study population included all women aged between
50 and 100 years who were registered at a general
practice in the UK that provide their computerized
medical records to The Health Improvement Network
(THIN) research database. General practitioners (GPs)
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play a key role in the UK health-care system, as they are
responsible for primary health care and specialist refer-
rals [5]. The data recorded in THIN include demo-
graphic information, prescription details, clinical
events, preventive care provided, specialist referrals,
hospital admissions and their major outcomes. The
study population was followed from 1990 up to 2003.
The period of follow-up was divided into 6-month
intervals and the age and the risk factors for fracture
and mortality were assessed at each interval.
Overall Design of the Model
Using data from this large cohort, an individual
patient-based pharmacoeconomic model was devel-
oped. The model included six outcomes: hip fracture
(or femur or pelvis), clinically symptomatic vertebral
fracture, clinically asymptomatic vertebral fracture,
wrist fracture (or clavicle, scapula or rib), humerus
fracture (or tibia or ﬁbula), and death. Two separate
analyses were conducted. The ﬁrst analysis included
those from the study population without a fracture
history. The second analysis included all patients who
developed a fracture (excluding morphometric verte-
bral fractures) during the simulation. In each analysis,
the outcomes between those using bisphosphonates or
not were compared.
Probabilities of Fracture or Death
The individual probabilities for fracture and death
were calculated using Cox proportional hazards
models. The methodology was similar to that previ-
ously applied to an analysis of oral glucocorticoid
users [6]. We ﬁrst ﬁtted regression models with age and
the various clinical risk factors. Backward regression
was conducted using a signiﬁcance level of 0.05. Then,
the ﬁnal Cox models were used to estimate the long-
term probability of fracture or death (i.e., survivor
function). The survivor function provides the long-
term risk for each set of patient characteristics [6]. We
investigated possible statistical interactions between
age and the risk factors (i.e., whether the relative risk
(RR) of risk factors differed across age). Interactions
between the various risk factors were not evaluated
because of the large number of possible combinations.
Various methods were used to test the ﬁtting of the
Cox models, including visual evaluation of the propor-
tional hazards assumption and a comparison of the
observed and predicted fracture probabilities. The Cox
models were developed separately for each of the four
different fracture types and death. Because of the
strong interaction between age and various risk
factors, the Cox model for death was ﬁtted separately
for each 10-year age stratum.
Two sets of clinical risk factors were used in the
calculation of individual probabilities for fracture and
mortality. The ﬁrst set included risk factors that have
been validated in a large meta-analysis of prospective
epidemiological studies, including BMI, smoking, frac-
ture history, use of oral glucocorticoids, and history of
rheumatoid arthritis [7]. In order to evaluate the extent
of variation of cost-effectiveness, additional risk
factors, which were associated in a previous study with
an increased risk of fracture, were also measured [8].
These included prescribing in the 6 months before
central nervous system medication (anticonvulsants,
hypnotics/anxiolytics, antidepressants, antipsychotics,
and anti-Parkinsonian drugs), recorded history of early
menopause, and of falls in the 6 to 18 months before.
The presence of the following diseases was also noted:
chronic obstructive pulmonary disease and asthma,
cerebrovascular accident, heart failure, and inﬂamma-
tory bowel disease. For patients with any of these
diseases, presence of a record indicating a GP visit or
hospitalization for these diseases in the 6 months
before was also measured. BMI was included as cat-
egorical variable (low BMI < 20, normal BMI 20–26,
and high BMI  26).
As vertebral fractures are under diagnosed in the
UK general clinical practice and systematic morphom-
etry was not routinely done by GPs, we adjusted the
vertebral fracture rate. The rate of (morphometric)
vertebral fractures, as reported in the European Pro-
spective Osteoporosis Study, was about 18 times
higher than those in THIN [9]. We multiplied the
THIN vertebral rates by half of this ratio, a more
conservative approach, in line with estimates from a
recent pharmacoeconomic analysis [10]. One-third of
these fractures were considered to be clinically symp-
tomatic and the remaining morphometric vertebral
fractures.
Modeling the Cost-Effectiveness
Using the individual mortality and fracture probabili-
ties, the outcomes were simulated over a 10-year
period, with simulation of outcomes at each 3-month
period of time. It was assumed that bisphosphonates
were given for 5 years, with a linear offset of the pro-
tective effect over the remaining 5 years of the model
[3]. Out of the total study population, 5000 patients
were randomly sampled and the age and risk factors
were used to calculate the individual fracture and mor-
tality rates. Over the course of the model, the indi-
vidual rates were adjusted for increasing age and, in
case of fracture occurrence in the model, for fracture
history. This simulation was repeated 20 times using
different cohorts of 5000 people. In the analysis for
cost-effectiveness with different levels of baseline
5-year fracture risk, the total population was divided
into 20 subgroups of fracture risk (as determined from
age and both sets of clinical risk factors). Linear regres-
sion analysis (with polynomial terms) was used to
estimate the predicted cost-effectiveness at different
levels of 5-year fracture risk.
Cost-Effectiveness and Patient Heterogeneity 349
Costs and Assumptions
The cost data and other assumptions used in the model
are listed in Table 1 [3]. The costs for prescriptions, GP
visits, and BMD scans were accrued at the beginning of
each 3-month period. If a patient died, it was assumed
that this occurred at the midpoint of the 3-month
interval. If a fracture occurred, it was assumed that any
losses in quality or quantity of life started to occur at
the next 3-month interval of time. If a patient suffered
a fracture and died in the same 3-month interval, the
order of these events was determined randomly. Life-
time costs were estimated for each patient in the simu-
lation who experienced a fracture.
In this study, it was assumed that bisphosphonates
reduced the risk of hip fractures by 33% (Table 1). No
differentiation was made between risedronate and alen-
dronate. The reason for this was that UK prescription
costs were similar for risedronate and alendronate and
a large meta-analysis found a statistically comparable
fracture efﬁcacy [11]. There are also no comparative
studies with fracture as outcome. The cost-effectiveness
of cyclical etidronate was not evaluated, given the
absence of clinical data on hip fracture efﬁcacy.
Postfracture Mortality
In order to estimate postfracture excess mortality, frac-
ture cases in the study population were randomly
matched to four controls (without a fracture) by age,
GP practice, and calendar time. Cases and con-
trols were then compared for 1-year mortality using
Cox proportional hazards models. Interaction terms
between fracture status and age were also included, if
statistically signiﬁcant. The excess mortality in the year
after the hip or clinically symptomatic vertebral frac-
tures was then estimated for each age, based on the
survivor function of the Cox model (i.e., the difference
in 1-year risk between cases and controls). For the
other fractures, no post-fracture excess mortality was
assumed, as the excess risk was small. These estimates
for excess mortality were used to adjust the mortality
in the 1 year after a hip or clinically symptomatic
vertebral fracture. It was assumed that fracture preven-
tion also avoided this excess mortality.
Calculation of Quality-Adjusted Life Years
Lifetime quality-adjusted life-years (QALYs) were
estimated for each patient in the simulation who
experienced a hip, clinically symptomatic vertebral,
humerus, or wrist fracture. The calculation of the gain
in QALYs was estimated using a similar approach as
the National Institute for Clinical Excellence (NICE)
[3]. Age-speciﬁc information on the quality of life
(QoL) in the general population was obtained from
literature [12]. The number of years alive with and
without postfracture excess mortality was calculated
and age-speciﬁc EuroQol (EQ-5D) utilities were
then assigned, with and without postfracture loss of
QoL, as reported in Table 1. The incremental cost-
effectiveness ratio for the cost to gain one QALY was
then calculated by dividing the difference in total costs
between the two strategies (bisphosphonates or not) by
the differences in number of QALYs. Morphometric
Table 1 Cost data and assumptions used in the model
Costs Bisphosphonate prescriptions (for 1 year): £284*
BMD measurement: £34*
GP visit: £18*
Hip fracture leading to nursing home entry: age 40–69, £31,299 (year 1), £23,562 (subsequent years); age 70–79,
£32,606 (year 1), £24,240 (subsequent years); age 80+, £34,654 (year 1), £25,357 (subsequent years)*
Other hip fracture: age 40–69, £5157 (year 1); age 70–79, £6487 (year 1); age 80+, £8538 (year 1)*
Clinically symptomatic vertebral fracture: age 40–69, £477 (year 1), £222 (subsequent years); age 70–79, £539 (year 1),
£222 (subsequent years); age 80+, £581 (year 1), £222 (subsequent years)*
Wrist fracture: age 40–79, £359 (year 1); age 80+, £585 (year 1)*
Humerus fracture: age 40–79, £1024 (year 1); age 80+, £1024 (year 1)*
Health utility† Hip fracture leading to nursing home entry: 0.4 (ﬁrst and subsequent years)*
Other hip fracture: 0.83 (year 1), 0.925 (subsequent years)*
Clinically symptomatic vertebral fracture: 0.83 (year 1), 0.93 (subsequent years)*
Wrist fracture: 0.981 (year 1)*
Humerus fracture: 0.794 (year 1), 0.973 (subsequent years)*
Assumptions BMD measurement (baseline) only in patients <65 years*
No GP costs for patients aged 75 years or older; one-third of patients aged below
75 years require one additional GP visit per year*
One-third of vertebral fractures are clinically symptomatic [23]
Percentage of patients that move from the community to a nursing home after a hip fracture: age 40–59, 0%; age 60–79,
4%; age 80–89, 12%; age 90+, 17%*
Annual discounting: costs, 6%; beneﬁts, 1.5%*
Fracture risk reduction due to bisphosphonate: hip, RR = 0.67; vertebral, RR = 0.59; wrist and humerus, RR = 0.81*
*Data and assumptions from the assessment report on the clinical effectiveness and cost-effectiveness of prevention and treatment of osteoporosis, as prepared by the National
Institute for Clinical Excellence [3].
†Multipliers for the proportionate effect of a fracture on the health utility [3].
BMD, bone mineral density; GP, general practitioner; RR, relative risk.
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vertebral fractures were not associated in the model
with any loss in quality or quantity of life, but were
indicators of fracture history and increased risk of
fracture.
Random Variability
The random variability of the cost-effectiveness ratios
was determined in two steps. First, the fracture and
mortality probabilities used in each simulation were
randomly selected from a normal distribution based on
the mean and standard deviation of the parameter as
observed in the THIN population. The second step
used the cost-effectiveness estimates as observed in the
20 reiterations of the model. Nonparametric boot-
strapping techniques were used to estimate the 95%
conﬁdence interval (CI), repeating the analysis 10,000
times. The 95% CI was based on the 2.5 and 97.5
percentiles of the distribution of the bootstrapping
results [13]. The 95% CI for the cost-effectiveness at
different levels of 5-year fracture risk was based on the
linear regression analyses of 2.5 and 97.5 percentiles of
the distribution of the bootstrapping results.
Validation of Model
In literature, it has been recommended that statistical
models that predict outcomes are validated in indepen-
dent data sets [14]. Therefore, we obtained informa-
tion from a random age-stratiﬁed sample of 50,000
women aged 50 years from the General Practice
Research Database (GPRD). During the period of
follow-up, the occurrence of the various fracture types
was noted. Each vertebral fracture was assumed to
have occurred nine times (a similar adjustment for
underdiagnosis of vertebral fractures as used in the
main analysis). The proportion of fractures that would
have been prevented by bone protection was based on
the estimate for bisphosphonate efﬁcacy. The cost per
fracture prevented was the number of fracture pre-
vented divided by the total costs for bone protection
during the period of follow-up. The cost per QALY
gained could not be validated given the additional
requirement for lifetime data post fracture on mortal-
ity and QoL, which were not available. We also vali-
dated the model by populating it with the data from a
previous NICE assessment report (using their fracture
incidence and mortality rates, RR increases because of
low BMD or fracture history, cost data, and efﬁcacy
estimates) [15].
Results
Study Population
The study population consisted of 332,306 women
who were aged between 50 and 100 years and who did
not have a fracture history at baseline. The average
duration of follow-up was 5.9 years (median 4.7
years). There were 5597 women with hip and 1509
women with clinically symptomatic vertebral frac-
tures. Strong risk factors for fracture included age, low
BMI, fall and fracture history. Mortality was strongly
related to age, low BMI, smoking history, and fall
history. Within the different age groups, the patients
with higher fracture risk, due to presence of clinical
risk factors, had higher mortality, compared with
patients with lower fracture risk. As shown in Table 2,
mortality was increased in the 1 year after a hip and
clinically symptomatic vertebral fracture.
Cost-Effectiveness
The outcomes of the model in fracture incidence and
mortality over the 10 years of the simulation are dis-
played in Table 3. As shown in Table 4, bisphospho-
nate therapy was more cost-effective in the older
women and in women with a fracture history. Also, it
was found that cost-effectiveness varied within age
groups by baseline risk of fracture. Considering the
effect of risk factors, a large inﬂuence of BMI was
Table 2 Excess 1-year mortality in fracture cases (absolute
difference in 1-year mortality between fracture cases and
controls)
Age (year) Hip (%) Vertebral (%)
50–59 2.4 2.3
60–69 4.4 3.5
70–79 7.5 5.2
80–89 11.4 6.7
90+ 13.6 6.6
Table 3 Rates of fracture and mortality in the simulation in patients not using bisphosphonates*
Age (year)
Without fracture history (%) With fracture history (%)
Died
Hip
fracture
Vertebral
fracture†
Wrist
fracture
Humerus
fracture Died
Hip
fracture
Vertebral
fracture†
Wrist
fracture
Humerus
fracture
50–59 4.4 0.8 3.3 3.8 2.9 5.2 1.7 7.6 6.6 5.1
60–69 10.7 2.4 7.1 5.1 3.5 10.4 4.2 13.2 8.0 5.8
70–79 25.6 5.9 10.7 5.7 3.8 25.3 9.9 19.7 8.5 6.1
80–89 50.2 9.2 10.3 5.2 3.4 54.2 15.0 18.3 7.7 5.4
90+ 75.6 9.6 7.6 4.0 2.7 84.4 13.9 11.6 5.1 3.6
*Individual fracture and mortality probabilities of model based on age,body mass index, smoking, fracture history, use of oral glucocorticoids, and history of rheumatoid arthritis.
†Including clinically symptomatic and asymptomatic vertebral fracture.
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noticed (Table 5). Patients with low BMI (<20) had
considerable better cost-effectiveness than patients
with high BMI (26).
Long-Term Fracture Risk Required for Cost-Effectiveness
The cost per QALY gained was estimated for patients
with different baseline risks for hip or osteoporotic
fractures (Fig. 1). Using a cost-acceptability ratio of
£30k per QALY gained, bisphosphonate treatment
became cost-effective for patients with a 5-year risk of
9.3% (95% CI 8.0–10.5%) for osteoporotic fractures
and of 2.1% (95% CI 1.5–2.7%) for hip fractures. The
threshold for a cost-acceptability ratio of £20k was
11.1% (95% CI 9.8–12.4%) for osteoporotic fractures
and 3.0% (95% CI 2.3–3.8%) for hip fractures.
Costs-Effectiveness and BMD
Using published data on the risk of osteoporotic frac-
tures at different T-scores, the cost per QALY gained
was estimated for different T-scores (Table 6). Bispho-
sphonate therapy was not cost-effective at age 60 in
patients at threshold of osteoporosis who did not have
a fracture history or other clinical risk factors. But
cost-effectiveness would be achieved in these patients if
risk factors independent of BMD were present with a
RR of 2.8 (using a cost-acceptability ratio of £30k).
Sensitivity Analyses
Table 7 shows the results of the sensitivity analyses.
The proportion of clinically symptomatic vertebral
fractures or post-fracture mortality estimates did not
Table 4 Cost (£000) per QALY gained stratiﬁed by fracture history, age, and baseline fracture risk*
No fracture history Fracture history
5-year hip
fracture risk (%)
Cost per QALY
gained (95% CI)
5-year hip
fracture risk (%)
Cost per QALY
gained (95% CI)
Age 50–59 years 0.4 270 (70–653) 0.9 38 (31–45)
Low baseline fracture risk 0.3 406 (132–805) 0.6 58 (44–77)
High baseline fracture risk 0.5 192 (63–434) 1.4 35 (26–48)
Age 60–69 years 1.2 60 (44–82) 2.2 26 (21–33)
Low baseline fracture risk 0.7 136 (60–272) 1.3 51 (31–84)
High baseline fracture risk 1.8 36 (28–46) 3.1 23 (18–28)
Age 70–79 years 3.2 20 (17–23) 5.4 8 (6–11)
Low baseline fracture risk 1.7 31 (27–35) 3.0 17 (14–22)
High baseline fracture risk 4.7 18 (14–24) 7.1 8 (6–11)
Age 80–89 years 5.9 9 (7–12) 9.8 <0 (<0–2)
Low baseline fracture risk 3.9 17 (12–23) 5.6 8 (5–12)
High baseline fracture risk 8.6 6 (2–10) 12.3 <0 (<0–<0)
Age 90+ years 7.6 8 (6–10) 12.6 1 (<0–2)
Low baseline fracture risk 5.1 17 (13–22) 7.6 10 (6–13)
High baseline fracture risk 10.7 4 (<0–9) 16.3 <0 (<0–<0)
*Each age group was divided into four quartiles of fracture risk as based on clinical risk factors (excluding age).
CI, conﬁdence interval; QALY, quality-adjusted life-year.
Table 5 Cost (£000) per QALY gained for patients with different risk factors
Prevalence (%)
No fracture history Fracture history
Age 60–79 Age 80+ Age 60–79 Age 80+
Body mass index
Low (<20) 6.7 23 1 11 <0
High (26) 44.5 71 23 22 12
Recorded history of early menopause
Yes 0.1 29 0 10 <0
No 99.9 54 11 27 4
RA
Yes 1.7 38 10 16 3
No 98.3 55 10 18 3
IBD
Yes 0.6 33 8 15 2
No 99.4 50 8 20 3
COPD/asthma
Yes 10.2 34 7 16 2
No 89.8 49 10 19 1
Recorded history of osteoporosis
Yes 2.5 31 5 17 1
No 97.5 47 11 25 5
COPD, chronic obstructive pulmonary disease; IBD, inﬂammatory bowel disease; QALY, quality-adjusted life-year; RA, rheumatoid arthritis.
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have major effects on the results of the study. It was
also found that the thresholds based on the median
costs per QALY gained (i.e., the middle value in the
repeated simulations) were considerably lower than
those based on the mean costs.
Validation of Model
In the validation data set, it was found that the cost per
fracture prevented was £30k. When applying our esti-
mates from our economic model to the validation
population, the cost per fracture prevented was found
to be comparable (£29k).
For patients without a fracture history and a
T-score of -2.5, the cost per QALY gained was £35k in
our model versus £39k (95% CI 26–67k) in the NICE
model at age 70, £10k versus £15k (95% CI 4–47k) at
age 80. The corresponding data for patients with a
fracture history was £51k versus £70k (95% CI
53–112k) at age 50, £52k versus £50k (95% CI
36–86k) at age 60, £16k versus £15k (95% CI 8–32k)
at age 70, and £1k versus less than £0 (95% CI
<0–16k) at age 80.
Discussion
In this study, it was found that cost-effectiveness for
bisphosphonates would be achieved for patients with a
5-year risk of 9.3% for osteoporotic fractures. An
important assumption in this study was that bisphos-
phonates reduced fractures in all study patients. The
efﬁcacy of bisphosphonates in individuals with low
BMD is well established, but they may be less efﬁca-
cious in individuals with normal BMD [16]. The
results of this study on cost-effectiveness of bisphos-
phonates can thus only be applied to patients, who
have a substantial risk of fracture and in whom bis-
phosphonates are likely to be clinically effective.
This study is the ﬁrst economic model in the ﬁeld of
osteoporosis that applied individualized fracture and
mortality risks, with risks varying between individual
patients. Many economic models also simulate out-
comes for individuals, but typically assume that all
individuals have identical risks [3,15]. There are several
limitations to this approach of assuming all patients are
average. First, results may not be generalizable to
patients with below- or above-average risks. For
example, patients with above-average risks (due to the
presence of other risk factors) may have shorter life-
expectancy, which will increase the cost per QALY
gained. The second limitation of this approach is that
the resulting intervention thresholds are based on a
restricted number of clinical characteristics, such as age
and BMD. A more attractive approach to economic
modelling is to base intervention thresholds on long-
term fracture probability and to use data from a diverse
population (with different risks) for the pharmaco-
economic model. A recent analysis highlighted the
importance that the data used for the cost-effectiveness
model accurately reﬂect the risk of the target population
[17]. Large well-validated health-care databases, such
as the GPRD, may provide useful information for cost-
effectiveness modelling, as they contain individual data
on risks of outcomes and death.
The data in this study (on costs, fracture incidence,
and mortality) were based on UK information. Our
ﬁndings on the fracture cost-effectiveness threshold
may only be generalizable to other countries if the
various input parameters of the model would be
0
30,000
60,000
90,000
120,000
0 5 10 15 20 25 30
5-year risk of fracture 
Figure 1 Cost (£) per quality-adjusted life-
year gained by 5-year baseline risk of hip or
osteoporotic fracture ( = hip fracture risk
without fracture history,  = hip fracture risk
with fracture history, = osteoporotic fracture
risk without fracture history, = osteoporotic
fracture risk with fracture history); fracture and
mortality probabilities based on age, body mass
index, smoking, fracture history, use of oral glu-
cocorticoids, and history of rheumatoid arthri-
tis, central nervous system medication use,
falls, early menopause, and history of chronic
diseases.
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comparable to those from other countries. Our model
could easily be populated with information from other
countries. Although cost data may be readily available,
individualized information on fracture incidence and
mortality may not be available in all countries, as these
data may not be systematically collected for large
general populations. But it would be useful if longitu-
dinal medical information would be collected in more
countries. This would allow better cost-effectiveness
assessment of medical therapies, based on individual-
ized information.
Kanis et al. recently developed thresholds for frac-
ture risks at which treatment would become cost-
effective. With a drug that reduces fractures by 35%
and an annual cost of $500, it was found that the
10-year hip probability at which this interven-
tion became cost-effective was 1.2% in women aged
50 years and 7.2% in women aged 85 years [18]. But
in this study, a single intervention threshold was esti-
mated. The reasons for multiple age-dependent inter-
vention thresholds in the study by Kanis et al. were
that it used average population data for both mortal-
ity and fracture risks, with information on age and
sex only. Nevertheless, a single intervention threshold
could be used if risk factor and age effects are
exchangeable. In this study, we found that younger
patients with several clinical risk factors had compa-
rable fracture and mortality risks as older patients
without risk factors and these patients had similar
intervention thresholds when also taking into account
the clinical risk factors. If this also applies to QoL
(on which we do not have any data), a single inter-
vention threshold can be used. The ﬁndings in this
study suggest that intervention thresholds should be
based on hip fracture risk. A doubling in the risk
of wrist and humerus fractures did not change the
hip fracture threshold. The threshold for risk of
osteoporotic fractures changed considerably, because
of the smaller impact of wrist and humerus on the
loss of QALYs.
Bisphosphonate treatment was found to be cost-
effective in almost all elderly women (>80 years). The
cost per QALY gained was below or around £20k,
irrespective of fracture history and presence of risk
factors. This ﬁnding could suggest that all elderly
women should be put on bisphosphonate treatment.
Nevertheless, our study assumed that bisphospho-
nates reduced the risk of fractures in all women, irre-
spective of their characteristics. This is unlikely to be
the case. Most clinical studies with bisphosphonates
have been conducted in women with osteoporosis [3].
A large randomized clinical study found that bispho-
sphonates had no effect on the risk of hip fractures
in elderly women selected primarily on the basis of
clinical risk factors, while signiﬁcant effects were
observed in women with low BMD [19]. Thus, the
ﬁndings of this study can help to identify women
for further diagnostic testing, such as BMD measure-
ment. Bisphosphonate treatment should be consid-
ered not only if a patient has a fracture risk above
the cost-effectiveness threshold, but also if bisphos-
phonates are likely to be clinically effective. An
elderly woman with normal BMD but increased risk
of fracture due to falling tendency should not be
prescribed a bisphosphonate, as there is no clinical
evidence for fracture reduction in patients with these
characteristics.
We found that bisphosphonate therapy was con-
siderably more cost-effective in patients with low
BMI. This was related both to the inverse relation-
ship between BMI and risk of fracture and to the
higher prevalence of other clinical risk factors in
patients with low BMI. Several studies have consis-
tently reported that patients with low weight or BMI
have an increased risk of osteoporosis. A review of
clinical predictors of osteoporosis concluded that
body weight less than 59 kg may be a simple and
reasonably sensitive but nonspeciﬁc measure for
selecting women for further diagnostic testing [20].
This observation and the ﬁnding of better cost-
Table 7 Sensitivity analyses for cost-effectiveness threshold (at £20k and £30k) of 5-year risk of hip or osteoporotic fractures
Sensitivity analysis
Hip fractures Osteoporotic fractures
Threshold
£20k (%)
Threshold
£30k (%)
Threshold
£20k (%)
Threshold
£30k (%)
Overall (mean) 3.0 2.1 11.0 9.3
Overall (median) 2.6 1.7 10.4 8.5
No discounting 2.6 1.8 10.2 8.5
Offset of bisphosphonate effects within 2 years 4.8 3.6 13.9 11.9
RR = 0.50 of fracture reduction at all sites by
bisphosphonates
1.7 1.2 8.4 7.1
RR = 0.80 of fracture reduction at all sites by
bisphosphonates
8.0 5.5 18.3 15.0
20% of vertebral fractures clinically symptomatic 3.6 2.5 11.2 9.5
Post-fracture excess mortality after hip and clinically
symptomatic fractures using NICE estimates [3]
3.3 2.3 11.6 9.6
Nursing home admission in 25% of hip fracture cases 1.8 1.3 8.6 7.4
Doubling of risk of wrist and humerus fractures 3.0 2.0 16.1 13.9
NICE, the National Institute for Clinical Excellence; RR, relative risk.
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effectiveness with low BMI suggest that elderly
women with low BMI should be targeted for further
diagnostic testing [21].
There are various limitations of this study. Our
ﬁndings are based on a complex mathematical model.
We evaluated the key underlying assumptions utilized
and its overall predictive capacity performed well.
Nevertheless, we did not evaluate all possible interac-
tions and the model may therefore have overestimated
or underestimated risks for certain combinations of
risk factors. Another limitation was that we did not
have information on all risk factors for fracture (such
as BMD, exercise, or diet), which would improve the
accuracy of prediction for an individual patient. Also,
our estimates for the conﬁdence intervals for cost-
effectiveness did not take into account the statistical
uncertainty around the magnitude of bisphosphonate
efﬁcacy. Our estimates for the loss of QoL due to a
fracture were similar to those used by the NICE, but
the evidence base for some of the estimates is limited
[3,15]. Similarly, there are only few data on the level of
nursing admission after a hip fracture, although this
was an important determinant of the intervention
threshold. In this study, we assumed that the preven-
tion of hip fractures resulted in a reduction of mortal-
ity. There are, however, no empiric data to indicate
that there is indeed a survival advantage associated
with the prevention of fracture. But an analysis of hip
fracture cases suggested that part of the excess mortal-
ity can be attributed to the hip fracture rather than to
comorbidity [22].
In conclusion, this study allowed the calculation
of the threshold for cost-effective intervention with
bisphosphonates in a general population of elderly
women. These intervention thresholds can be calcu-
lated from age and clinical risk factors and may be
used to identify those patients who might beneﬁt from
BMD assessment and from therapy with bisphospho-
nates. Pharmacoeconomic models based on individual
risks of outcomes may improve the targeting in a cost-
effective manner of therapy to patients.
Source of ﬁnancial support: TP van Staa was previously
employed by Procter & Gamble Pharmaceuticals, Egham,
UK. He currently works for the General Practice Research
Database.
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